NasdaqCM - Delayed Quote • USD
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
At close: April 25 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -1.09 | -1.2 | -5.2 | -5.12 |
| Low Estimate | -1.22 | -1.43 | -6.38 | -5.57 |
| High Estimate | -0.96 | -0.98 | -4.03 | -4.67 |
| Year Ago EPS | -4.24 | -2.05 | -10.31 | -5.2 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -4.09 | -3.1 | -2.06 | -2.36 |
| EPS Actual | -4.24 | -2.05 | -2.05 | -1.81 |
| Difference | -0.15 | 1.05 | 0.01 | 0.55 |
| Surprise % | -3.70% | 33.90% | 0.50% | 23.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.09 | -1.2 | -5.2 | -5.12 |
| 7 Days Ago | -1.09 | -1.2 | -5.2 | -5.12 |
| 30 Days Ago | -1.09 | -1.2 | -5.2 | -5.12 |
| 60 Days Ago | -1.87 | -1.92 | -8.1 | -9.04 |
| 90 Days Ago | -1.52 | -1.57 | -6.59 | -7.36 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CRBP | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 74.30% | -- | -- | 2.60% |
| Next Qtr. | 41.50% | -- | -- | 13.40% |
| Current Year | 49.60% | -- | -- | 5.20% |
| Next Year | 1.50% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Oppenheimer: Outperform to Outperform | 3/13/2024 |
| Upgrade | Jefferies: Hold to Buy | 3/6/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 1/29/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 8/9/2023 |
| Upgrade | Oppenheimer: Perform to Outperform | 5/10/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 3/8/2023 |
Related Tickers
JANX Janux Therapeutics, Inc.
47.10
-2.30%
ELEV Elevation Oncology, Inc.
3.6450
-6.06%
APM Aptorum Group Limited
5.48
-1.44%
CYTK Cytokinetics, Incorporated
64.80
-3.02%
DAWN Day One Biopharmaceuticals, Inc.
13.21
-13.03%
VINC Vincerx Pharma, Inc.
0.8967
-3.58%
KURA Kura Oncology, Inc.
19.00
+1.33%
CGEM Cullinan Therapeutics, Inc.
19.25
+1.91%
CADL Candel Therapeutics, Inc.
6.43
+6.28%
LPTX Leap Therapeutics, Inc.
3.1700
-3.65%